Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 2/20 | 0.51 |
| ▸ | ALPL | P05186 | 3/20 | 0.49 |
| ▸ | IDH1 | O75874 | 2/20 | 0.47 |
| ▸ | HTR1B | P28222 | 1/20 | 0.47 |
| ▸ | CMA1 | P23946 | 1/20 | 0.47 |
| ▸ | DAO | P14920 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21729202 | 0.84 | PLA2G2A (0.65) | PLA2G2ASMN1; SMN2 | |
| SCHEMBL9911076 | 0.84 | PLA2G2A (0.48) | PLA2G2ADAO | |
| SCHEMBL5580883 | 0.80 | PLA2G2A (0.46) | PLA2G2A | |
| SCHEMBL21729183 | 0.79 | DAO (0.46) | PLA2G2AIDH1DAO | |
| SCHEMBL11838787 | 0.78 | PLA2G2A (0.54) | PLA2G2ADAO | |
| SCHEMBL21157861 | 0.74 | GPR55 (0.48) | IDH1HTR1BCMA1DAOSMN1; SMN2 | |
| SCHEMBL2099512 | 0.74 | CHRM2 (0.66) | HTR1BCMA1MAOB | |
| SCHEMBL31546428 | 0.74 | NOTUM (0.54) | PLA2G2ASMN1; SMN2 | |
| SCHEMBL13684194 | 0.72 | MEN1 (0.55) | — | |
| SCHEMBL21729229 | 0.72 | PLA2G2A (0.45) | PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200055831-A1 | HETEROCYCLIC P2X7 ANTAGONISTS | BREYE THERAPEUTICS APS (DK) | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055831-A1 | HETEROCYCLIC P2X7 ANTAGONISTS | P2RY1, P2RX1, P2RX3 | PLA2G2A 2693/4885ALPL 4071/4885IDH1 1639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.